Results 31 to 40 of about 581 (108)

24 | Management of advanced basal cell carcinoma with hedgehog inhibitors: a real-world prospective comparative study

open access: yesDermatology Reports
Background: Hedgehog Pathway Inhibitors (HHIs) should be offered to patients with advanced BCC as a first line treatment. Two systemic HHIs are currently available: sonidegib and vismodegib.
Italian Melanoma Intergroup
doaj   +1 more source

Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series

open access: yesCurrent Oncology, 2023
Nevoid basal-cell carcinoma syndrome (Gorlin syndrome) is characterized by numerous cutaneous basal cell carcinomas mediated by mutations in the hedgehog pathway. Vismodegib or sonidegib represent promising treatment options.
Raquel Wescott, Wolfram Samlowski
doaj   +1 more source

The Therapeutic Potential of Purmorphamine Across Disease Models

open access: yesJournal of Cellular and Molecular Medicine, Volume 30, Issue 17, September 2026.
ABSTRACT Purmorphamine (PUR) is a trisubstituted purine compound that selectively activates Smoothened receptor, thereby initiating Sonic Hedgehog (Shh) signalling—a pathway critical for embryonic patterning, neuronal specification and tissue regeneration across multiple organ systems. Dysregulation of Shh signalling has been implicated in degenerative
Ashis Dhar   +4 more
wiley   +1 more source

Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma [PDF]

open access: yes, 2017
Background: Sonidegib (LDE225) is a potent, selective hedgehog (Hh) inhibitor of Smoothened. This study explored the safety and pharmacokinetics of sonidegib in children with relapsed/recurrent tumors followed by a phase II trial in pediatric and adult ...
Chisholm, J   +37 more
core   +2 more sources

Clinical and economic benefits of using sonidegib in the 1-line therapy of patients with locally advanced basal cell carcinoma

open access: yesФармация и фармакология (Пятигорск)
One of the key factors in ensuring the availability of modern treatments and choosing the optimal therapy for patients is the clinical and economic characteristics of new medical technologies.The aim: to assess the clinical and economic feasibility of ...
O. I. Ivakhnenko   +3 more
doaj   +1 more source

A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma

open access: yesJournal of Skin Cancer, 2017
Objectives. Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy.
Dawn Odom   +7 more
doaj   +1 more source

The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area

open access: yesDermatology and Therapy, 2023
Introduction Basal cell carcinoma (BCC) is the most common skin malignancy in Caucasians. Globally, about 20% of BCCs involve the periocular region. The treatment of periocular BCC may be very challenging because of its proximity to the intracranial ...
Alessia Villani   +5 more
doaj   +1 more source

Sphingosine‐1‐Phosphate Receptor 1 Regulates Competition Dependent Astrocyte Morphogenesis and Tiling in Murine Cortex

open access: yesGlia, Volume 74, Issue 8, August 2026.
Neuronal contact‐induced expression of S1PR1 in astrocytes is regulated by JAK‐STAT3 signaling. Astrocytic S1PR1 modulates cortical astrocyte morphogenesis. Astrocytic S1PR1 regulates astrocyte territorial overlap/tiling in a competition dependent manner.
Jean Patrick M. Gonzales   +9 more
wiley   +1 more source

Toward Sustainable Carbonylation Reactions Enabled by CO Surrogates in Green Solvents

open access: yesChemSusChem, Volume 19, Issue 13, 14 July 2026.
Carbonylation reactions offer a sustainable route to valuable carbonyl compounds. This review highlights methodologies that exploit carbonylative coupling to drastically enhance process sustainability, avoiding the direct use of CO through CO surrogates and promoting syntheses in green solvents potentially derived from renewable and sustainable sources.
Francesco Messa   +2 more
wiley   +1 more source

25 | A phase II, open-label study to improve compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas – the SONIBEC trial

open access: yesDermatology Reports
Background: Sonidegib is an effective treatment for laBCC, but it is associated with a risk of treatment-related adverse events (TRAEs), causing treatment discontinuation.
Italian Melanoma Intergroup
doaj   +1 more source

Home - About - Disclaimer - Privacy